It was explained at the AGM that the top line results only included clinical assessments of the boys. The laboratory results eg CD49D was only available to the Board at end of January. This is because the external laboratory company waits until all blood tests are at their site and they run all samples at an allocated time slot of their choosing. That is why the Board haven’t made any final decision regarding the future of the drug. But in the meantime the ongoing dosing of boys has stopped as no clinical benefit was seen. The boys are also released from the study to afford them opportunity to enroll in other trials if they wish.In addition detailed investigations into manufacturing are occurring as is standard practice in such situations.
We wait for the Laboratory results that the Board will receive end of January..
PER Price at posting:
0.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)